

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/680,998		10/08/2003	Rudi Beyaert	2676-4554.1US	7433	
24247	7590	03/30/2006		EXAMINER		
TRASK BI	TTIS		ROOKE, AGNES BEATA			
P.O. BOX 2	550				·	
SALT LAKE CITY, UT 84110				ART UNIT PAPER NUM		
				1653		

DATE MAILED: 03/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)					
Office Action Summary			10/680,998	В	BEYAERT ET AL.				
			Examiner		Art Unit				
			Agnes B. R		1653				
Period fo	The MAILING DATE of this commun or Reply	ication appe	ears on the	cover sheet with the c	orrespondence ad	ldress			
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M resions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this com period for reply is specified above, the maximum st re to reply within the set or extended period for reply eply received by the Office later than three months a d patent term adjustment. See 37 CFR 1.704(b).	MAILING DA s of 37 CFR 1.13 nunication. atutory period wi will, by statute,	TE OF THI 6(a). In no ever ill apply and will cause the applic	S COMMUNICATION nt, however, may a reply be time expire SIX (6) MONTHS from the cation to become ABANDONED	l. ely filed the mailing date of this c O (35 U.S.C. § 133).				
Status									
1)	Responsive to communication(s) file	ed on							
· —	•	2b)⊠ This	_	on-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
•	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)🖂	4)⊠ Claim(s) <u>1-17</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
6)[Claim(s) is/are rejected.								
7)									
8)⊠	Claim(s) 1-17 are subject to restricti	on and/or e	lection requ	uirement.					
Applicati	on Papers								
9) The specification is objected to by the Examiner.									
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
	Applicant may not request that any obje		-						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority ι	ınder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notice 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (F mation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date			4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite	O-152)			

Art Unit: 1653

1

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, drawn to a method for screening for a compound where SEQID NO:8 is used, classified in class 514, subclass 12.
- II. Claims 1-9, drawn to a method for screening for a compound where SEQID NO:9 is used, classified in class 514, subclass 12.
- III. Claims 1-9, drawn to a method for screening for a compound where SEQID NO:19 is used, classified in class 514, subclass 12.
- IV. Claims 1-9, drawn to a method for screening for a compound where SEQID NO:2 is used, classified in class 514, subclass 12.
- V. Claims 1-9, drawn to a method for screening for a compound where SEQID NO:5 is used, classified in class 514, subclass 12.
- VI. Claims 10-17, drawn to a method for screening for a compound where SEQ ID NO:8 is used, classified in class 514, subclass 12.
- VII. Claims 10-17, drawn to a method for screening for a compound where **SEQ ID NO:9** is used, classified in class 514, subclass 12.
- VIII. Claims 10-17, drawn to a method for screening for a compound where **SEQ ID NO:19** is used, classified in class 514, subclass 12.
- IX. Claims 10-17, drawn to a method for screening for a compound where **SEQ ID NO:2** is used, classified in class 514, subclass 12.

X. Claims 10-17, drawn to a method for screening for a compound whereSEQ ID NO:5 is used, classified in class 514, subclass 12.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-V and invention VI-X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, inventions I-X refer to a method of screening a compound, however inventions I-V are distinct from inventions VI-X because inventions VI-X have additional steps in the method, such as preparing a read out system, which steps are distinct from inventions I-V, which do not utilize this additional step. Therefore, the inventions are distinct since they posses different steps and different modes of operation.

Inventions I-V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, inventions I-V utilize different peptides of different SEQ ID Nos: 8, 9, 19, 2, or 5, which have different structure and thus different function. Therefore the inventions are distinct.

Inventions VI-X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case,

inventions VI-X utilize different peptides of different SEQ ID Nos: 8, 9, 19, 2, or 5, which have different structure and thus different function. Therefore the inventions are distinct.

Page 4

Because the inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for the examination purposes as indicated is proper.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the Invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Agnes Rooke whose telephone number is 571-272-2055. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status

Application/Control Number: 10/680,998

Art Unit: 1653

information about the PAIR system, see http://pair-direct.uspto.gov. or call 866-217-Janen Cachane Carton PW

9197.

AR

KAREN COCHRANE CARLSON, PH.D. PRIMARY EXAMINER

Page 5